

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan (MHRA-100951-PIP01-23-M03) and to the deferral

MHRA-100951-PIP01-23-M04

### **Scope of the Application**

#### **Active Substance(s)**

FOSTEMSAVIR TROMETHAMINE

#### **Condition(s)**

Treatment of human immunodeficiency virus (HIV-1) infection

#### **Pharmaceutical Form(s)**

Prolonged-release tablet

#### **Route(s) of Administration**

ORAL USE

#### **Name / Corporate name of the PIP applicant**

ViiV Healthcare UK Ltd

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, ViiV Healthcare UK Ltd submitted to the licensing authority on 19/11/2025 11:53 GMT an application for a Modification

The procedure started on 02/12/2025 13:43 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100951-PIP01-23-M04

Of 03/03/2026 07:33 GMT

On the adopted decision for FOSTEMSAVIR TROMETHAMINE (MHRA-100951-PIP01-23-M04) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for FOSTEMSAVIR TROMETHAMINE, Prolonged-release tablet , ORAL USE .

This decision is addressed to ViiV Healthcare UK Ltd, 79 New Oxford Street, London, UNITED KINGDOM, WC1A 1DG

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of human immunodeficiency virus (HIV-1) infection The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age  
Pharmaceutical form(s): Prolonged-release tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of human immunodeficiency virus (HIV-1) infection

## 2.2 Indication(s) targeted by the PIP:

Treatment of HIV-1 infection as part of a combination therapy in paediatric patients who have no more than 2 remaining available fully active antiretroviral therapies.

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age

## 2.4 Pharmaceutical Form(s):

Prolonged-release tablet

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of a prolonged-release tablet. Study 2 deleted during procedure EMEA-001687-PIP01-14-M03.
Non-Clinical Studies	2	Study 3 Oral pre- and postnatal development study in rats. Study 4 Ten-week oral toxicity study in juvenile rats with 8 weeks of recovery.
Clinical Studies	2	Study 5 Open-label, single-arm trial to evaluate pharmacokinetics, safety, antiviral activity and acceptability/ palatability of fostemsavir in combination with optimised background therapy (OBT) in HIV-1 infected children and adolescents from 6 to less than 18 years of age who are failing their current combination antiretroviral therapy (cART) and have at least dual-class antiretroviral (ARV) resistance. Study 6 deleted during procedure EMEA-001687-PIP01-14-M03. Study 7 Open-label, randomised study in healthy adult volunteers to determine the bioavailability of the prolonged-release tablet developed in Study 1 relative to the adult prolonged release tablet.

		Study 8 deleted during procedure EMEA-001687-PIP01-14-M03.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	2	Study 9 Modelling and simulation study to support the use of the fostemsavir in HIV-infected children and adolescents from 6 to less than 18 years of age who are failing their current cART and have at least dual-class ARV resistance. Study 10 Extrapolation study to support the use of the fostemsavir in HIV-infected children and adolescents from 6 to less than 18 years of age who are failing their current cART and have at least dual-class ARV resistance.
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	Yes
<b>Date of completion of the paediatric investigation plan:</b>	31/03/2027
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes